AzTrials
AzTrials

Colorectal CancerPhase 1MEDIPLEXNCT02777710

Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers

A Phase 1 study testing Pexidartinib and Durvalumab in people with Colorectal Cancer and Pancreatic Cancer, run by Centre Leon Berard at 2 sites in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) are the most common gastrointestinal cancers in Western countries and are both associated with significant morbidity and mortality. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Pexidartinib and Durvalumab
Could I receive a placebo?
No, everyone receives an active treatment
How many people
48 participants
Where
2 sitesFrance
Study dates
Jun 2016to Dec 2019
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or female patients aged ≥ 18 years at time of inform consent signature
  • Histologically proven adenocarcinoma of the pancreas or colorectal, at the advanced or metastatic stage
  • Prior therapy for the metastatic/advanced disease. For PDAC, treatment with at least one previous line of chemotherapy. For CRC, treatment with at least one previous line of therapy.
  • Availability of a representative tumor specimen in paraffin blocks (preferred) or at least 20 unstained slides or a fresh tumor biopsy* before C1D1 with an associated pathology report. *: If there is no available archival material, a tumor biopsy has to be performed after patient' consent.
  • Extension part: patients to be enrolled in this part of the study should have biopsiable disease (i.e. at least one lesion with a diameter of at least 10 mm, visible by medical imaging and accessible to percutaneous or endoscopic sampling)
  • At least one measurable lesion according to RECIST 1.1
Show all 14Show fewer
  • ECOG PS 0-1
  • Royal Marsden score of 0 or 1
  • Adequate organ and marrow function as defined below based on medical records and according to lab tests performed within 72 hours before C1D1 (Hemoglobin ≥ 10.0 g/dL, Absolute neutrophil count (ANC) ≥ 1.5 x 109/L, Platelets ≥ 100 x 109/L; Lymphocyte count ≥ 0.5 x 109/L, Serum creatinine ≤ 1.5 × ULN and CL>60 mL/min using Cockcroft-Gault formula, or MDRD for patients over 65 years (Appendix 7- Creatinin clearance calculation), AST and ALT ≤ ULN, Serum bilirubin ≤ ULN (in the absence of Gilbert's syndrome), INR or PT ≤ 1.5 × ULN unless patient is receiving anticoagulant therapy as long as INR/PT or PTT is within therapeutic range of intended use of anticoagulants, aPTT ≤ 1.5 × ULN unless patient is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants, Serum potassium, magnesium, and calcium levels (high or low) ≤ Grade 1
  • Minimal wash-out period for prior treatment (minimal time required from prior treatment and C1D1 of this study):Chemotherapy, immunotherapy, or radiation therapy > 14 days; Immunosuppressive medication > 28 days, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid; Live attenuated vaccination > 30 days; Strong CYP3A4 inducers or inhibitors > 14 days; Major surgical procedure, open biopsy (excluding skin cancer resection and screening tumor biopsy), or significant traumatic injury > 14 days (the wound must have healed).
  • Women of child-bearing potential must have a negative serum pregnancy test within 72 hours before C1D1 and must agree to use 2 effective forms of contraception from the time of the negative pregnancy test up to 6 months after the last dose of study drug. Effective forms of contraception include abstinence, hormonal contraceptive in conjunction with a barrier method, or a double barrier method. Women of non-child-bearing potential may be included if they are either surgically sterile or have been postmenopausal for ≥ 1 year.
  • Fertile men must agree to use effective methods of birth control during the study and for up to 6 months after the last dose of study drug.
  • Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.
  • Patients must be covered by a medical insurance.

Who cannot join

  • Cancer disease considered curable with surgery or radiotherapy.
  • Previous therapy with specific CTLA-4, CSF1, CSF1-R, PD-1 and/or PD-L1 inhibitors
  • Persisting significant toxicities related to prior treatments i.e. ≥ Grade 2 AE according to CTCAE V4 except alopecia and biological values defined in inclusion criteria
  • History of any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent,
  • Inability to take oral medication (i.e. to swallow capsules of Pexidartinib) or significant nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption of oral medication.
  • Hypersensitivity to the active substance or excipient or other humanized monoclonal antibody (a history of hypersensitivity reaction to cetuximab is allowed, but patient should be closely monitored for infusion-related reaction)
Show all 10Show fewer
  • Symptomatic or active leptomeningeal or parenchymal brain metastases. Patients with previously treated brain metastases (either by surgery, radiotherapy or radiosurgery) may be enrolled if stable, off steroids, on imaging and clinically, for at least 4 weeks.
  • Active or prior/history of disease/medical condition listed below: Documented autoimmune disease within the past 2 years except for autoimmune hypothyroidism on a stable dose of thyroid supplementation and patients with type 1 diabetes mellitus on a stable dose of insulin. NOTE: Subjects with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded; Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3 electrocardiograms (ECGs) using Fredericia's Correction; Clinically significant cardiac disease or congestive heart failure > New York Heart Association (NYHA) class 2. Patients must not have unstable angina (anginal symptoms at rest) or new-onset angina within the last 3 months or myocardial infarction within the past 6 months; Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis); Primary immunodeficiency; Allogeneic organ transplant; Known clinical diagnosis of tuberculosis; Any uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV); Any psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent; Active secondary malignancy unless the malignancy is not expected to interfere with the evaluation of safety and is approved by the sponsor. Examples of the latter include basal or squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, and isolated elevation of prostate-specific antigen. Patients with a completely treated prior malignancy and no evidence of disease for ≥ 2 years are eligible; hepatobiliary diseases including biliary tract diseases, autoimmune hepatitis, inflammation, fibrosis, cirrhosis of liver caused by viral, alcohol, or genetic reasons. Gilbert's disease is allowed if Total Bilirubine is ≤ 1.5 × ULN.
  • Need for the following concomitant medications/interventions not permitted during the study treatment period: Any investigational anticancer therapy other than the protocol-specified therapies; Any concurrent chemotherapy, radiotherapy (except palliative radiotherapy on a non-target lesion after discussion with the sponsor), immunotherapy, biologic or hormonal therapy for cancer treatment, other than any stated in the protocol; Immunosuppressive medications including, but not limited to systemic corticosteroids at doses exceeding 10 mg/d of prednisone or equivalent, methotrexate, azathioprine, and TNF-α blockers. Use of immunosuppressive medications for the management of investigational product-related AEs or in subjects with contrast allergies is acceptable; Live attenuated vaccines; Strong inhibitors and inducers of CYP3A4; Major surgery
  • Pregnant or breast-feeding female patients.

Trial locations and contacts

2 sites in 1 country.

France2 sites

  • Centre Léon Bérard

    Lyon, 69008

  • IUCT-oncopole

    Toulouse, 31059

Other trials in France

About this study

Official title: A Dose Escalation Phase I Study With an Extension Part Evaluating the Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With a Small Molecule CSF-1R Tyrosine Kinase Inhibitor (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers

Colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) are the most common gastrointestinal cancers in Western countries and are both associated with significant morbidity and mortality. An intriguing similarity between CRC and PDAC is the fact that the newly developed immune checkpoint inhibitors, especially PD1/PDL1 inhibitors, seem to have limited efficacy as single agents in both of these tumor types. Recent preclinical studies point towards alternatively activated (M2-type) macrophages as possible culprits in inducing local immune protection from cytotoxic T cells and resistance to PD1/PD-L1 targeted agents. We hypothesize that CSF1R blockade will deplete the tumor microenvironment of M2 macrophages, thus favoring the induction of a cytotoxic anti-tumor T-cell response following PD-L1 blockade with an anti-PD-L1 monoclonal antibody. So we propose to conduct a Phase I dose escalation study in order to evaluate the safety and clinical activity of a combined treatment associating an anti-CSF1R (PEXIDARTINIB) with an anti-PD-L1 (DURVALUMAB) in patients with advanced/metastatic colorectal or pancreatic cancers. Dose escalation part will determine the Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of Pexidartinib given in combination with Durvalumab. Extension part will evaluate the clinical activity of the combination at the RP2D.

Read the detailed description

This study will be a 2-part Phase I study comprising a dose-finding escalation part (to determine MTD/RP2D, safety and PK) followed by an extension part at RP2D. In the dose-escalation part, successive cohorts of 3 patients will receive Pexidartinib (given orally every day at escalating doses, five dose levels possible, Plexxikon), in combination with Durvalumab (given IV every 4 weeks at a fixed dose of 1500mg, AstraZeneca). The dose escalation scheme will be done using a Likelihood Continual Reassessment Method (CRML). After each new cohort of 3 patients is evaluated, model will be fitted and results will be discussed in a teleconference between the investigators, the sponsor, representatives of AstraZeneca and Plexxikon, and the statistician who will decide of the next dose to be assigned to the next cohort (Dose Escalation Meetings). In both parts, patients will continue to receive study drugs as long as they experience clinical benefit in the opinion of the investigator or until unacceptable toxicity including DLTs or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL. The extension part will comprise two independent cohorts of patients with pancreatic adenocarcinoma (PDAC cohort) or colorectal adenocarcinoma (CRC cohort) and biopsiable disease, and will allow the assessment of anti-tumor activity based on a Gehan design allowing to quickly identify treatments with low efficacy.

Being tested
Pexidartinib, Durvalumab
Medical subject headings
Colorectal Neoplasms, Pancreatic Neoplasms, Neoplasm Metastasis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PexidartinibDrug

    Also called PLX3397

    Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.

  • DurvalumabDrug

    Also called MEDI4736

    Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.

Study groups in NCT02777710
Study groupRoleWhat they receive
Combination Pexidartinib-DurvalumabExperimental* DURVALUMAB (MEDI4736): therapeutic Class anti-PD-L1 mAb, given IV every 4 weeks at a fixed dose of 1500mg, AstraZeneca * PEXIDARTINIB (PLX3397): therapeutic Class Kinase inhibitor targeting CSF1-R, Flt3 and Kit. Administered daily as split dose regimen, orally. Five dose-levels possible in dose escalation part: 400mg 5 days on 2 days off (intermittent schedule), 400 mg, 600 mg, 800 mg or 1000 mg. In this combination trial, Pexidartinib should be taken first and the Durvalumab IV infusion should be scheduled 1 hour after the Pexidartinib morning dose.
Receives: Drug: Pexidartinib; Drug: Durvalumab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. part 1 (dose escalation part) : Dose-Limiting Toxicities (DLT)

    A DLT is defined as one of the following toxicities occurring during the DLT assessment window (i.e. 1 cycle = 28 days) related to Durvalumab, Pexidartinib or both: any Grade ≥4 irAE, any Grade ≥3 irAE, that does not downgrade to Grade 2 within 3 days after onset of the event despite optimal medical management or does not downgrade to ≤ Grade 1 or baseline within 14 days, any Grade 2 pneumonitis that does not resolve to ≤ Grade 1 within 3 days of the initiation of maximal supportive care, Grade ≥ 4 neutropenia (ANC < 500/μL) lasting ≥ 7 days, Grade ≥ 3 febrile neutropenia, Grade ≥ 4 thrombocytopenia associated with clinically significant bleeding and lasting > 72 hours, AST/ALT > 10 x ULN, AST/ALT > 3x ULN with bilirubin >2x ULN, any other study drug related toxicity considered significant in the opinion of the investigators, any other Grade ≥ 3 major organ adverse event with some exceptions.

    Measured: during the DLT assessment window (i.e. 1 cycle = 28 days)

  2. part 2 (extension part) : objective response rate (ORR)

    The objective response rate (ORR) will be defined as the proportion of patients (described on the efficacy-evaluable population) who achieve complete response (CR) or partial response (PR) as best overall response at 16 weeks of treatment. ORR is based on tumor assessments (measurements according to RECIST 1.1 criteria).

    Measured: 16 weeks of treatment

Secondary outcomes (5)

  1. The duration of response (DoR)

    in parts 1 and 2

    Measured: from the time of first documented response (CR or PR as per RECIST 1.1 criteria) until the first documented progression or date of death due to underlying cancer, or censored at the date of the last available tumor assessment, assessed up to 52 weeks.

  2. Progression-Free Survival (PFS)

    in parts 1 and 2, PFS will be estimated using the Kaplan-Meier method.

    Measured: from the date of inclusion until the date of the first progression or date of death from any cause, up to 52 weeks.

  3. Adverse events reporting

    based mainly on the frequency of adverse events based on the common toxicity criteria (CTCAE-V4.03) grade.

    Measured: from the signature of the ICF and the first intake of study drug until 90 days after the last study drugs intake or until initiation of a new anti-cancer treatment

  4. Area under the Pexidartinib plasma concentration (AUC) versus time curve

    analyzed by measurement of area under the plasma concentration-time curve (AUC 0-4h, AUC 0-6h. For each time frame: at pre-dose of both study drugs and at 1, 2, 4 and 6 hours post- Pexidartinib dosing.

    Measured: Cycle 1 Day 1, C1D15, C2D1 and C3D1

  5. Peak Pexidartinib plasma concentration (Cmax)

    Cmax will define Tmax (time at wich Cmax is observed). For each time frame: at pre-dose of both study drugs and at 1, 2, 4 and 6 hours post- Pexidartinib dosing.

    Measured: Cycle 1 Day 1, C1D15, C2D1 and C3D1

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 May 2016 (estimated)
  2. Study startJun 2016
  3. Primary completionNov 2019
  4. Study completionDec 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
48 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02777710
Sponsor's protocol ID
ET15-037 (MEDIPLEX)
Other IDs
2015-002438-31, 2015
Acronym
MEDIPLEX
Status last verified
Sep 2021
First submitted
12 May 2016
Last updated
5 Sep 2021
Results posted
No
Data monitoring committee
Yes
Individual data sharing
No

Publications

  • Voissiere A, Gomez-Roca C, Chabaud S, Rodriguez C, Nkodia A, Berthet J, Montane L, Bidaux AS, Treilleux I, Eberst L, Terret C, Korakis I, Garin G, Perol D, Delord JP, Caux C, Dubois B, Menetrier-Caux C, Bendriss-Vermare N, Cassier PA. The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers. Sci Transl Med. 2024 Jan 24;16(731):eadd1834. doi: 10.1126/scitranslmed.add1834. Epub 2024 Jan 24.

    PubMed 38266104

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Pexidartinib and Durvalumab in people with Colorectal Cancer and Pancreatic Cancer, run by Centre Leon Berard at 2 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 14 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

part 1 (dose escalation part) : Dose-Limiting Toxicities (DLT) (time frame: during the DLT assessment window (i.e. 1 cycle = 28 days)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02777710, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Sep 2021.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in